Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Hypertension ; 81(9): 1996-2005, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39041205

RESUMEN

BACKGROUND: Nocturnal hemodialysis (nHD) restores the attenuated brachial artery vasodilator responsiveness of patients receiving conventional intermittent hemodialysis (iHD). Its impact on coronary vasodilatation is unknown. METHODS: We evaluated 25 patients on hemodialysis who fulfilled transplant criteria: 15 on iHD (4-hour sessions, 3 d/wk) and 10 on nHD (≈40 h/wk over 8-10-hour sessions) plus 6 control participants. Following diagnostic angiography, left anterior descending (LAD) coronary flow reserve and mean luminal diameter were quantified at baseline and during sequential intracoronary administration of adenosine (infusion and bolus), nitroglycerin (bolus), acetylcholine (infusion), acetylcholine coinfused with vitamin C, and, finally, sublingual nitroglycerin. RESULTS: Coronary flow reserve in those receiving nHD was augmented relative to iHD (3.28±0.26 versus 2.17±0.12 [mean±SEM]; P<0.03) but attenuated, relative to controls (4.80±0.63; P=0.011). Luminal dilatations induced by intracoronary adenosine and nitroglycerin were similar in nHD and controls but blunted in the iHD cohort (P<0.05 versus both). ACh elicited vasodilatation in controls but constriction in both dialysis groups (both P<0.05, versus control); vitamin C coinfusion had no effect. Sublingual nitroglycerin increased mid-left anterior descending diameter and reduced mean arterial pressure in controls (+15.2±2.68%; -16.00±1.60%) and in nHD recipients (+14.78±5.46%; -15.82±1.32%); iHD responses were markedly attenuated (+1.9±0.86%; -5.89±1.41%; P<0.05, all comparisons). CONCLUSIONS: Coronary and systemic vasodilator responsiveness to both adenosine and nitroglycerin is augmented in patients receiving nHD relative to those receiving iHD, whereas vasoconstrictor responsiveness to acetylcholine does not differ. By improving coronary conduit and microvascular function, nHD may reduce the cardiovascular risk of patients on dialysis.


Asunto(s)
Nitroglicerina , Diálisis Renal , Vasodilatación , Vasodilatadores , Humanos , Femenino , Masculino , Diálisis Renal/métodos , Persona de Mediana Edad , Vasodilatadores/administración & dosificación , Vasodilatadores/farmacología , Vasodilatación/efectos de los fármacos , Vasodilatación/fisiología , Nitroglicerina/farmacología , Nitroglicerina/administración & dosificación , Anciano , Circulación Coronaria/efectos de los fármacos , Circulación Coronaria/fisiología , Acetilcolina/farmacología , Acetilcolina/administración & dosificación , Fallo Renal Crónico/terapia , Fallo Renal Crónico/fisiopatología , Arteria Braquial/efectos de los fármacos , Arteria Braquial/fisiopatología , Adenosina/administración & dosificación , Vasos Coronarios/diagnóstico por imagen , Vasos Coronarios/fisiopatología , Vasos Coronarios/efectos de los fármacos , Angiografía Coronaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...